NeOnc Technologies

Neonc Technologies was founded to develop a pipeline of new drugs and potentially new technologies for the treatment of glioma and meningioma. The company's main development, NEO100, is undergoing phase 2 testing. The company received $22.2 million in September from investors including Neucen Biomedical Co.

 

The global market for the treatment of brain tumors may reach $6.2 billion by 2033. It is now estimated at 3.1 billion. The average annual growth rate is expected to be 7.2%.

 

_____________________________

The number of employees:

5-15

_____________________________

Headquarters:

Woodland Hills, California, USA